What’s the current market cap for Perspective Therapeutics stock?

Perspective Therapeutics (CATX) has a market cap of $335m as of June 16, 2026.

What is the P/E ratio for Perspective Therapeutics stock?

The price to earnings (P/E) ratio for Perspective Therapeutics (CATX) stock is 0 as of June 16, 2026.

Does Perspective Therapeutics stock pay dividends?

No, Perspective Therapeutics (CATX) stock does not pay dividends to its shareholders as of June 16, 2026.

When is the next Perspective Therapeutics dividend payment date?

Perspective Therapeutics (CATX) stock does not pay dividends to its shareholders.

What is the beta indicator for Perspective Therapeutics?

Perspective Therapeutics (CATX) has a beta rating of 1.76. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy Perspective Therapeutics stock | $CATX Share Price

13:30

15:10

16:45

18:25

20:00

About Perspective Therapeutics

Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.

Ticker

$CATX

Sector

Health

Primary listing

AMEX

Employees

165

Headquarters

Seattle, United States

Website

www.perspectivetherapeutics.com

CATX Metrics

BasicAdvanced

$335m

-$1.36

1.76

What the Analysts think about CATX

Analyst ratings (Buy, Hold, Sell) for Perspective Therapeutics stock.

Bulls say / Bears say

Perspective Therapeutics dosed the first patients in new cohorts of its Phase 1/2a studies for [212Pb]VMT-α-NET and [212Pb]PSV359, broadening its pipeline into neuroendocrine and solid tumors. (Reuters)

Updated interim Phase 1/2a data for [212Pb]VMT-α-NET showed a 43% objective response rate in Cohort 2 at AACR 2026, underscoring robust anti-tumor efficacy and manageable safety. (Reuters)

As of March 31, 2026, Perspective held $271 million in cash, cash equivalents, and short-term investments, underpinning a cash runway into late 2027 to fund planned clinical and operational milestones. (Nasdaq)

Research and development expenses surged by approximately 50% year-over-year to $21.4 million in Q1 2026, accelerating cash burn prior to any product revenue. (SEC 8-K)

Net loss widened to $26.2 million ($0.25 per share) in Q1 2026 versus $18.2 million in Q1 2025, reflecting escalating operating losses that will likely necessitate further capital raises. (SEC 8-K)

The February 2026 equity offering issued 39.6 million new shares and 6.6 million pre-funded warrants, boosting share count by over 50% and diluting existing shareholders. (SEC 8-K)

Data summarised monthly by Lightyear AI. Last updated on 7 Jun 2026.

CATX Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

CATX Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $CATX

Capital at risk

Market closed

Upcoming events

No upcoming events